One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
New challenges in vascular biology and medicine: from unravelling the mechanisms of neointima formation to the prevention of amputations and of ischaemic stroke
Filippo Crea
doi : 10.1093/eurheartj/ehab224
Volume 42, Issue 18, 7 May 2021, Pages 1715–1719,
Hyperinflammation as underlying mechanism predisposing patients with cardiovascular diseases for severe COVID-19
Ulf Landmesser, Irina Lehmann, Roland Eils
doi : 10.1093/eurheartj/ehab191
Volume 42, Issue 18, 7 May 2021, Pages 1720–1721,
A journey through clinic and research
Fabrizio Montecucco
doi : 10.1093/eurheartj/ehab184
Volume 42, Issue 18, 7 May 2021, Pages 1721–1723,
From a Cardiology Institute to a COVID centre in Mexico
Jorge E Aceituno-Melgar, MD, Jes?s Mart?nez-Gutiérrez, MD, Francisco Baranda-Tovar, MD
doi : 10.1093/eurheartj/ehaa743
Volume 42, Issue 18, 7 May 2021, Pages 1723–1726,
StatinWISE sheds new light on statin-related muscle symptoms
Giovanna Liuzzo, Carlo Patrono
doi : 10.1093/eurheartj/ehab220
Volume 42, Issue 18, 7 May 2021, Pages 1726–1727,
The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study
The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study
doi : 10.1093/eurheartj/ehaa956
Volume 42, Issue 18, 7 May 2021, Pages 1728–1738,
The aim of this study was to evaluate the temporal pattern of amputations in patients with type 2 diabetes mellitus (T2DM), the risk of amputations by new and older anti-diabetic drugs (ADDs), and the interplay of peripheral artery disease (PAD) with therapy and amputation risk.
Do SGLT2 inhibitors increase the risk of amputation? Make haste slowly
Charalambos Vlachopoulos, Dimitrios Terentes-Printzios, Konstantinos Tsioufis
doi : 10.1093/eurheartj/ehaa1022
Volume 42, Issue 18, 7 May 2021, Pages 1739–1741,
Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality
Stefan J Schunk, Marcus E Kleber, Winfried M?rz, Shichao Pang, Stephen Zewinger
doi : 10.1093/eurheartj/ehab107
Volume 42, Issue 18, 7 May 2021, Pages 1742–1756,
Inflammation plays an important role in cardiovascular disease (CVD) development. The NOD-like receptor protein-3 (NLRP3) inflammasome contributes to the development of atherosclerosis in animal models. Components of the NLRP3 inflammasome pathway such as interleukin-1? can therapeutically be targeted. Associations of genetically determined inflammasome-mediated systemic inflammation with CVD and mortality in humans are unknown.
Can a single genetic variant explain residual cardiovascular risk by modifying NLRP3 expression?
Nikolina Papac-Milicevic, Christoph J Binder
doi : 10.1093/eurheartj/ehab201
Volume 42, Issue 18, 7 May 2021, Pages 1757–1759,
Coronary stent CD31-mimetic coating favours endothelialization and reduces local inflammation and neointimal development in vivo
Sergio Diaz-Rodriguez, Charlotte Rasser, Jules Mesnier, Pascale Chevallier, Romain Gallet
doi : 10.1093/eurheartj/ehab027
Volume 42, Issue 18, 7 May 2021, Pages 1760–1769,
The rapid endothelialization of bare metal stents (BMS) is counterbalanced by inflammation-induced neointimal growth. Drug-eluting stents (DES) prevent leukocyte activation but impair endothelialization, delaying effective device integration into arterial walls. Previously, we have shown that engaging the vascular CD31 co-receptor is crucial for endothelial and leukocyte homeostasis and arterial healing. Furthermore, we have shown that a soluble synthetic peptide (known as P8RI) acts like a CD31 agonist. The aim of this study was to evaluate the effect of CD31-mimetic metal stent coating on the in vitro adherence of endothelial cells (ECs) and blood elements and the in vivo strut coverage and neointimal growth.
Refining drug-eluting stent technologies: from engineering to basic science
Alexandra Lansky, Hyung Chun, Cody Pietras, Yasin Hussain
doi : 10.1093/eurheartj/ehab091
Volume 42, Issue 18, 7 May 2021, Pages 1770–1772,
A proteomic atlas of the neointima identifies novel druggable targets for preventive therapy
Michael Wierer, Julia Werner, Jana Wobst, Adnan Kastrati, Ganildo Cepele
doi : 10.1093/eurheartj/ehab140
Volume 42, Issue 18, 7 May 2021, Pages 1773–1785,
In-stent restenosis is a complication after coronary stenting associated with morbidity and mortality. Here, we sought to investigate the molecular processes underlying neointima formation and to identify new treatment and prevention targets.
Hitting the right channels to spread a ‘no-restenosis’ message to vascular wall cells
Giuseppina Caligiuri, Gregory Franck
doi : 10.1093/eurheartj/ehab144
Volume 42, Issue 18, 7 May 2021, Pages 1786–1788,
Supracardiac atherosclerosis in embolic stroke of undetermined source: the underestimated source
George Ntaios, Max Wintermark, Patrik Michel
doi : 10.1093/eurheartj/ehaa218
Volume 42, Issue 18, 7 May 2021, Pages 1789–1796,
The term ‘embolic stroke of undetermined source’ (ESUS) is used to describe patients with a non-lacunar ischaemic stroke without any identified embolic source from the heart or the arteries supplying the ischaemic territory, or any other apparent cause. When the ESUS concept was introduced, covert atrial fibrillation was conceived to be the main underlying cause in the majority of ESUS patients. Another important embolic source in ESUS is the atherosclerotic plaque in the carotid, vertebrobasilar, and intracranial arteries, or the aortic arch—collectively described as supracardiac atherosclerosis. There is emerging evidence showing that the role of supracardiac atherosclerosis is larger than it was initially perceived.
Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1): a crucial driver of atherosclerotic cardiovascular disease
Alexander Akhmedov, Tatsuya Sawamura, Chu-Huang Chen, Simon Kraler, Daria Vdovenko
doi : 10.1093/eurheartj/ehaa770
Volume 42, Issue 18, 7 May 2021, Pages 1797–1807,
Cardiovascular diseases (CVDs), specifically lipid-driven atherosclerotic CVDs, remain the number one cause of death worldwide. The lectin-like oxidized low-density lipoprotein (LDL) receptor-1 (LOX-1), a scavenger receptor that promotes endothelial dysfunction by inducing pro-atherogenic signalling and plaque formation via the endothelial uptake of oxidized LDL (oxLDL) and electronegative LDL, contributes to the initiation, progression, and destabilization of atheromatous plaques, eventually leading to the development of myocardial infarction and certain forms of stroke. In addition to its expression in endothelial cells, LOX-1 is expressed in macrophages, cardiomyocytes, fibroblasts, dendritic cells, lymphocytes, and neutrophils, further implicating this receptor in multiple aspects of atherosclerotic plaque formation. LOX-1 holds promise as a novel diagnostic and therapeutic target for certain CVDs; therefore, understanding the molecular structure and function of LOX-1 is of critical importance. In this review, we highlight the latest scientific findings related to LOX-1, its ligands, and their roles in the broad spectrum of CVDs.
Which biomarker to use, when to start, and how to improve adherence for reducing atherosclerotic cardiovascular disease risk?
Kwang Kon Koh
doi : 10.1093/eurheartj/ehaa948
Volume 42, Issue 18, 7 May 2021, Page 1808,
Examine low-density lipoprotein, remnants, and lipoprotein(a) in parallel in high risk patients
Martin B?dtker Mortensen, B?rge Gr?nne Nordestgaard
doi : 10.1093/eurheartj/ehaa969
Volume 42, Issue 18, 7 May 2021, Pages 1809–1810,
A case of tortuous anatomy: cervical aortic arch
Finn Y van Driest, J Lauran St?ger, Arthur J H A Scholte, J Wouter Jukema, Anastasia D Egorova
doi : 10.1093/eurheartj/ehaa713
Volume 42, Issue 18, 7 May 2021, Page 1811,
Leukocytoclastic vasculitis associated myocarditis: differentiating inflammatory from inherited heart muscle disease
Mohammed Y Khanji, Neha Sekhri
doi : 10.1093/eurheartj/ehaa840
Volume 42, Issue 18, 7 May 2021, Page 1812,
Corrigendum to: European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism
doi : 10.1093/eurheartj/ehab176
Volume 42, Issue 18, 7 May 2021, Page 1807,
Erratum to: Conducting Clinical Trials in Heart Failure During (and After) the COVID-19 Pandemic: An Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
doi : 10.1093/eurheartj/ehab190
Volume 42, Issue 18, 7 May 2021, Page 1810,
The European Medicines Agency's approval of proprotein convertase subtilisin/kexin type 9 inhibitors
Eberhard Blind, Pieter A de Graeff, Illiana Meurs, Frank Holtkamp, Ania Baczynska
doi : 10.1093/eurheartj/ehv673
Volume 42, Issue 18, 7 May 2021, Pages e2–e3,
